Biotechnology company Enhanced Genomics has received new investment in its Series A programme, the company has announced. Enhanced Genomics, known for pioneering 3D multi-omics to rapidly identify high-confidence, genetically-validated drug targets for common diseases, has received $19 million (£14 million) from BGF, Parkwalk and Meltwind. The funding will be used… Read More
DDW’s Megan Thomas went to Cambridge, UK, to learn more about what’s happening in this life science epicentre. She spoke with several local companies and attended events. The first of this series was a conversation with Nicola Thompson, CEO of TRIMTECH Therapeutics. Here, DDW summarises what was learnt about Enhanced… Read More
Biotechnology company Enhanced Genomics has announced a strategic partnership with The ALBORADA Drug Discovery Institute at the University of Cambridge. Funded by Alzheimer’s Research UK, The ALBORADA Drug Discovery Institute is developing the next generation of treatments for the diseases that cause dementia. The partnership… Read More
